Early neoplastic progression is complement independent

Neoplasia

Volumn 6, Issue 6, 2004, Pages 768-776

  De Visser, Karin E ^a   Korets, Lidiya V ^a   Coussens, Lisa M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Cancer; Complement; Immunity; Inflammation

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL INFILTRATION; CELL PROLIFERATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DYSPLASIA; EPITHELIUM TUMOR; FEMALE; GENE DELETION; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN TUMOR; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 11144279989     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04250     Document Type: Article

References (57)

1. Bissell MJ and Radisky D (2001). Putting tumors in context. Nat Rev Cancer 1, 46-54.
2. Coussens LM and Werb Z (2002). Inflammation and cancer. Nature 420, 860-867.
3. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100, 57-70.
4. Weitzman SA and Gordon LI (1990). Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76, 655-663.
5. Ness RB and Cottreau C (1999). Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91, 1459-1467.
6. Shacter E and Weitzman SA (2002). Chronic inflammation and cancer. Oncology 16, 217-226.
7. Ernst PB and Gold BD (2000). The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 54, 615-640.
8. Williams CS, Mann M, and DuBois RN (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18, 7908-7916.
9. Garcia-Rodriguez LA and Huerta-Alvarez C (2001). Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin non-steroidal antiinflammatory drugs. Epidemiology 12, 88-93.
10. Meier CR, Schmitz S, and Jick H (2002). Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22, 303-309.
11. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, and Hanley JA (2000). Nested case-control study of the effects of non-steroidal antiinflammatory drugs on breast cancer risk and stage. Br J Cancer 83, 112-120.
12. Cotterchio M, Kreiger N, Sloan M, and Steingart A (2001). Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10, 1213-1217.
13. Akre K, Ekstrom AM, Signorello LB, Hansson LE, and Nyren O (2001). Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 84, 965-968.
14. Gonzalez-Perez A, Rodriguez L, and Lopez-Ridaura R (2003). Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3, 1-12.
15. Prodeus AP, Zhou X, Maurer M, Galli SJ, and Carroll MC (1997). Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 390, 172-175.
16. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, and Carroll MC (1995). Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 92, 11490-11494.
17. Walport MJ (2001). Complement. First of two parts. N Engl J Med 344, 1058-1066.
18. Walport MJ (2001). Complement. Second of two parts. N Engl J Med 344, 1140-1144.
19. Sahu A and Lambris JD (2001). Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 180, 35-48.
20. Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S, Haase I, Lippert U, and Zuberbier T (1997). C3a and C5a stimulate chemotaxis of human mast cells. Blood 89, 2863-2870.
21. Johnson AR, Hugli TE, and Muller-Eberhard HJ (1975). Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 28, 1067.
22. DiScipio RG, Daffern PJ, Jagels MA, Broide DH, and Sriramarao P (1999). A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 162, 1127-1136.
23. Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, Siegbahn A, and Murphy PM (1996). C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 157, 1693-1698.
24. Lapiere JC, Guitart J, Ettlin DA, Chen DM, Amagai M, and Chan LS (1998). Preferential activation of the complement system in the lower epidermis of patients with pemphigus vulgaris. Br J Dermatol 139, 851-854.
25. Walters DM, Breysse PN, Schofield B, and Wills-Karp M (2002). Complement factor 3 mediates paniculate matter-induced airway hyperresponsiveness. Am J Respir Cell Mol Biol 27, 413-418.
26. Berstad AE, Brandtzaeg P, Stave R, and Halstensen TS (1997). Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis. Gut 40, 196-203.
27. Sugita Y, Morita E, Kawamoto H, Horiuchi K, Yamada S, Koro O, and Yamamoto S (2000). Correlation between deposition of immunocomponents and infiltration pattern of polymorphonuclear leukocytes in the lesions of chronic urticaria. J Dermatol 27, 157-162.
28. Halstensen TS, Mollnes TE, Garred P, Fausa O, and Brandtzaeg P (1990). Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 98, 1264-1271.
29. Drouin SM, Corry DB, Kildsgaard J, and Wetsel RA (2001). Cutting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 167, 4141-4145.
30. Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, Sohns B, Flemme N, Meyer zu Vilsendorf A, Grove M, et al. (2000). Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 165, 5401-5405.
31. Zhang Y, Ramos BF, and Jakschik BA (1995). The role of mast cells and their mediators in IgG-antigen complex-mediated inflammation. Am J Ther 2, 761-767.
32. Andoh A, Fujiyama Y, Araki Y, Kimura T, Tsujikawa T, and Bamba T (2001). Role of complement activation and mast cell degranulation in the pathogenesis of rapid intestinal ischemia/reperfusion injury in rats. Digestion 63 (Suppl 1), 103-107.
33. Szczepanik M, Akahira-Azuma M, Bryniarski K, Tsuji RF, Kawikova I, Ptak W, Kiener C, Campos RA, and Askenase PW (2003). B-1 B cells mediate required early T cell recruitment to elicit protein-induced delayed-type hypersensitivity. J Immunol 171, 6225-6235.
34. Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, and Diaz LA (1995). The role of complement in experimental bullous pemphigoid. J Clin Invest 95, 1539-1544.
35. Coussens LM, Hanahan D, and Arbeit JM (1996). Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 149, 1899-1917.
36. Arbeit JM, Munger K, Howley PM, and Hanahan D (1994). Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 68, 4358-4368.
37. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, and Hanahan D (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13, 1382-1397.
38. van Kempen LCL, Rhee JS, Dehne K, Lee J, Edwards DR, and Coussens LM (2002). Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation 70, 501-623.
39. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, and Hanahan D (2003). Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197, 1017-1028.
40. Rhee JS, Diaz R, Korets L, Hodgson JG, and Coussens LM (2004). TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 64, 952-961.
41. Coussens LM, Hanahan D, and Arbeit J (1996). Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 149, 1899-1917.
42. Coussens LM, Tinkle CL, Hanahan D, and Werb Z (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490.
43. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, and Giudice GJ (1993). A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92, 2480-2488.
44. Chen R, Fairley JA, Zhao ML, Giudice GJ, Zillikens D, Diaz LA, and Liu Z (2002). Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol 169, 3987-3992.
45. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, Dvorak HF, and Galli SJ (1998). Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med 188, 1135-1145.
46. Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, Kogel H, Welker P, Lippert U, Henz BM, and Moller A (1998). Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell 9, 875-884.
47. Fang KC, Wolters PJ, Steinhoff M, Bidgol A, Blount JL, and Caughey GH (1999). Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. J Immunol 162, 5528-5535.
48. Stevens RL, Friend DS, McNeil HP, Schiller V, Ghildyal N, and Austen KF (1994). Strain-specific and tissue-specific expression of mouse mast cell secretory granule proteases. Proc Natl Acad Sci USA 91, 128-132.
49. Reynolds DS, Stevens RL, Lane WS, Carr MH, Austen KF, and Serafin WE (1990). Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases. Proc Natl Acad Sci USA 87, 3230-3234.
50. Kimura T, Andoh A, Fujiyama Y, Saotome T, and Bamba T (1998). A blockade of complement activation prevents rapid intestinal ischaemia-reperfusion injury by modulating mucosal mast cell degranulation in rats. Clin Exp Immunol 111, 484-490.
51. Kawakami T and Galli SJ (2002). Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2, 773-786.
52. Woolhiser MR, Okayama Y, Gilfillan AM, and Metcalfe DD (2001). IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. Eur J Immunol 31, 3298-3307.
53. Janeway CA, Travers P, Walport M, and Shlomchik MJ (2001). Immunobiology: The Immune System in Health and Disease, 5th ed. Garland Publishing, New York.
54. Clynes R and Ravetch JV (1995). Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 3, 21-26.
55. Robbie-Ryan M, Tanzola MB, Secor VH, and Brown MA (2003). Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity. J Immunol 170, 1630-1634.
56. Sylvestre DL and Ravetch JV (1996). A dominant role for mast cell Fc receptors in the Arthus reaction. Immunity 5, 387-390.
57. Sylvestre DL and Ravetch JV (1994). Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 265, 1095-1098.